Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the (oligo)clonal expansion of myeloid progenitor cells. Despite advances in treatment, AML remains challenging to cure, particularly in patients with specific genetic abnormalities. Menin inhibitors have emerged as a promising therapeutic approach, targeting key genetic drivers of AML such as KMT2A rearrangements and NPM1 mutations. Here, we review the clinical value of menin inhibitors, highlighting their mechanism of action, efficacy, safety, and potential to transform AML treatment.

中文翻译：

---

我去了治疗急性髓性白血病的抑制剂。


急性髓系白血病 （AML） 是一种异质性血液系统恶性肿瘤，其特征是髓系祖细胞的（寡）克隆扩增。尽管治疗取得了进展，但 AML 仍然难以治愈，尤其是在具有特定遗传异常的患者中。Menin 抑制剂已成为一种很有前途的治疗方法，针对 AML 的关键遗传驱动因素，例如 KMT2A 重排和 NPM1 突变。在这里，我们回顾了 menin 抑制剂的临床价值，重点介绍了它们的作用机制、疗效、安全性和改变 AML 治疗的潜力。